[Therapeutic plasmapheresis procedures: An alternative to the disruption of the supply of polyvalent immunoglobulin in autoimmune pathologies. Medico-economic study].

Abstract

INTRODUCTION:

The supply of human polyvalent immunoglobulin has been under severe pressure for several years. This has led to a prioritisation of indications and a record increase in the amount of reimbursement without solving the problem of demand. Treatment by therapeutic plasmapheresis appears to be an alternative to be considered for the treatment of certain dysimmune diseseases. To discuss this alternative, we are conducting a medico-economic study comparing the polyvalent immunoglobulin strategy versus different therapeutic plasmapheresis system in the treatment of a chronic dysimmune disease.

POPULATION AND METHOD:

The medico-economic study was conducted using the example of a 75 kg patient with chronic polyradiculoneuritis dependent on chronic therapy with a comparison of sequential treatment with one session of therapeutic plasmapheresis versus a course of intravenous polyvalent immunoglobulin. The medico-economic study includes an evaluation from a public health care system perspective complemented by a hospital-based approach that justifies estimating the cost of different therapeutic plasmapheresis systems based on a bottom-up micro-costing approach.

RESULTS:

From the point of view of the care system, for information, a 20 g bottle of polyvalent immunoglobulin has a similar cost to a therapeutic plasmapheresis session. In our example, the cost of a maintenance treatment repeated every 2 to 4 weeks in chronic polyradiculoneuritis in a 75 kg patient is 1284.13 euros for a therapeutic plasmapheresis session versus 7331.60 to 9426.84 euros for a 1.5 to 2 mg/kg polyvalent immunoglobulin treatment. Furthermore, from the point of view of the hospital system, the cost of the different TT techniques evaluated varies moderately with the cost depending mainly on the quantity of albumin infused or the medical device used.

CONCLUSION:

In the chronic sequential treatment of chronic polyradiculoneuritis, the cost of therapeutic plasmapheresis could be lower than with polyvalent immunoglobulin from a healthcare system perspective. The cost to the health care facility between different therapeutic plasmapheresis techniques differs little. This study provides arguments suggesting that if therapeutic plasmapheresis can be implemented with a dedicated technical platform, it is a serious alternative to be considered without additional costs.

• Authors: Olivier Moranne, Clarisse Roux, Ioana Maria Ion, Sihame Chkair
• Journal: Nephrologie & therapeutique (Nephrol Ther) Vol. 18 Issue 3 Pg. 172-179 (Jun 2022) ISSN: 1872-9177 [Electronic] France
• Vernacular Title: Les techniques de plasmaphérèse thérapeutique : une alternative à la rupture d’approvisionnement en immunoglobuline polyvalente dans les pathologies auto-immunes. Étude médico-économique.
• PMID: 35644771 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Société francophone de néphrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.

Chemical References

• Immunoglobulins, Intravenous

Topics

• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Plasma Exchange
• Plasmapheresis (methods)
• Polyradiculoneuropathy (drug therapy)